

William Hogan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5191791/william-hogan-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

331
papers

3,687
citations

31
h-index

53
g-index

339
ext. papers

4,603
ext. citations

3.6
avg, IF

4.88
L-index

#	Paper	IF	Citations
331	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 4-10	4.7	242
330	Outcome of transplantation for myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 358-67	4.7	206
329	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>Leukemia</i> , 2013 , 27, 1322-7	10.7	168
328	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. <i>Bone Marrow Transplantation</i> , 2013 , 48, 557-61	4.4	124
327	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017 , 2, e89798	9.9	118
326	Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3264-74	2.2	111
325	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012 , 118, 1585-92	6.4	92
324	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2181-7	1.9	92
323	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018 , 131, 2846-2855	8.4	84
322	Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 1131-8	6.4	83
321	The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 605-616	4.7	71
320	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1323-1329	2.2	68
319	Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 87-93	4.7	66
318	Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. <i>Chest</i> , 2012 , 141, 442-450	5.3	61
317	Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 305-9	4.4	57
316	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. <i>Bone Marrow Transplantation</i> , 2006 , 37, 1003-8	4.4	55
315	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367	4.4	51

314	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1348-1356	4.7	51
313	Second auto-SCT for treatment of relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2013 , 48, 568-73	4.4	47
312	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1493-1503	4.7	45
311	Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. <i>British Journal of Haematology</i> , 2015 , 169, 77-80	4.5	44
310	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1189-211	6.4	39
309	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1617-1624	6.4	39
308	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017 , 52, 173-182	4.4	39
307	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Blood Research</i> , 2014 , 49, 100-6	1.4	38
306	Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. <i>JAMA Oncology</i> , 2017 , 3, 1253-1256	13.4	37
305	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1449-1455	4.4	37
304	Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1690-1695	4.7	34
303	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015 , 29, 741-4	10.7	33
302	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating antigenic factors. <i>Blood</i> , 2016 , 128, 2350-2358	2.2	33
301	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 598-605	4.7	32
300	Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016 , 18, 913-920	2.7	30
299	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020 , 95, 1511-1521	7.1	28
298	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , 2016 , 122, 2197-205	6.4	28
297	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016 , 6, e512	7	28

296	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018 , 8, 29	7	27
295	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2019 , 54, 204-211	4.4	27
294	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1478-1484	4.7	26
293	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, 649-654	7.1	26
292	Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. <i>Blood Cancer Journal</i> , 2017 , 7, e607	7	26
291	Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 760-2	6.4	26
290	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 4034-4042	7.8	26
289	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1020-1026	7.1	25
288	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1284-9	4.3	21
287	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1126-1132	4.4	20
286	Efficacy of biological agents in the treatment of Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018 , 183, 520-524	4.5	20
285	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018 , 32, 712-718	10.7	20
284	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017 , 52, 34-40	4.4	20
283	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012 , 120, 3138-3138	2.2	20
282	Emergencies in Hematology and Oncology. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 609-641	6.4	19
281	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2062-2076	2.2	19
280	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017 , 102, 1439-1445	6.6	19
279	Use of cyclosporine in hematopoietic cell transplantation. <i>Transplantation Proceedings</i> , 2004 , 36, 367S-371S	3.15	19

278	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1431-1439	4.7	18
277	Posttransplant autoimmune encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018 , 5, e497	9.1	17
276	Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1804-12	4.7	17
275	Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1724-30	1.9	17
274	Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2264-2269	4.7	17
273	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 579-83	4.7	16
272	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018 , 2, 1882-1888	7.8	16
271	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018 , 2, 769-776	7.8	16
270	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 546-9	2	15
269	Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. <i>Clinical Transplantation</i> , 2014 , 28, 1084-91	3.8	15
268	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015 , 29, 498-500	10.7	14
267	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1363-1374	6.4	14
266	Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1999 , 110, 77-81		14
265	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012 , 120, 739-739	2.2	14
264	Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1710-1716	4.7	14
263	Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant. <i>Journal of Clinical Apheresis</i> , 2015 , 30, 147-53	3.2	13
262	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018 , 8, 18	7	13
261	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1906-1913	4.7	13

260	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1753-1768	6.4	13
259	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 106	7	13
258	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2360-2364	4.7	13
257	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 308-315	1.9	12
256	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. <i>American Journal of Hematology</i> , 2017 , 92, 866-871	7.1	12
255	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2127-2132	4.7	12
254	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 56-58	6.4	12
253	Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2016 , 18, 216-26	2.7	12
252	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <i>Transfusion</i> , 2016 , 56, 518-27	2.9	12
251	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018 , 71, 60-62	2.7	11
250	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e108-e111	4.7	11
249	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021 , 11, 49	7	11
248	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2588-2597	1.9	10
247	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1623-38	6.4	10
246	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2013 , 3, e122	7	10
245	A phase 1 trial of Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1372-1377	4.4	10
244	Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. <i>European Journal of Haematology</i> , 2017 , 99, 275-282	3.8	10
243	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 699-704	2	10

242	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3849-3849	2.2	10
241	Overview of the progress on haploidentical hematopoietic transplantation. <i>World Journal of Transplantation</i> , 2016 , 6, 665-674	2.3	10
240	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018 , 182, 71-77	4.5	9
239	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1066-1071	7.1	9
238	Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 349-357.e2	2	8
237	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2737-2739	1.9	8
236	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018 , 103, 1229-1234	6.6	8
235	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1467-1474	6.4	8
234	Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <i>Leukemia Research</i> , 2015 , 39, 1207-1207	2.7	7
233	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020 , 10, 68	7	7
232	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020 , 34, 1898-1906	10.7	7
231	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 587-594	4.4	7
230	Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma. <i>Journal of Blood Medicine</i> , 2015 , 6, 45-53	2.3	7
229	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α -1-antitrypsin. <i>Blood Advances</i> , 2020 , 4, 6098-6105	7.8	7
228	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020 , 10, 121	7	7
227	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2039-2050	4.4	6
226	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1520-1525	4.7	6
225	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020 , 10, 36	7	6

224	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1592-1600	1.9	6
223	Infusion of autograft natural killer cell/CD14HLA-DR cell ratio predicts survival in lymphoma post autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 146-154	4.4	6
222	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
221	Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. <i>Blood Cancer Journal</i> , 2017 , 7, 647	7	6
220	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e39-41	2	6
219	Fulminant hepatic failure secondary to adenovirus following fludarabine-based chemotherapy for non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1145-50	1.9	6
218	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1775-1779	4.4	5
217	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2132-2137	4.4	5
216	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. <i>Human Immunology</i> , 2018 , 79, 532-536	2.3	5
215	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 945-955	4.7	5
214	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019 , 54, 442-447	4.4	5
213	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1542-1550	15.0	5
212	Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 80	22.4	5
211	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, E8-E10	7.1	5
210	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 990-999	1.9	5
209	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1144-1150	4.4	5
208	Implementation of a patient blood management program in hematopoietic stem cell transplantation (Editorial, p. 2763). <i>Transfusion</i> , 2019 , 59, 2840-2848	2.9	4
207	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020 , 189, e104-e108	4.5	4

206	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 326-333	4.4	4
205	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1714-5	1.9	4
204	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016 , 128, 1123-1123	2.2	4
203	Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. <i>Blood</i> , 2016 , 128, 2799-2799 ²⁻²		4
202	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. <i>Leukemia Research</i> , 2016 , 50, 112-115	2.7	4
201	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 165.e1-165.e11		4
200	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 764-767	1.9	4
199	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1297-1304	4.4	3
198	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2157-2159	4.7	3
197	The association of de novo anti-HLA-DPB1 donor-specific antibody formation and primary graft failure after allogeneic hematopoietic cell transplantation. <i>Human Immunology</i> , 2018 , 79, 861-864	2.3	3
196	A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.. <i>Blood</i> , 2004 , 104, 1505-1505	2.2	3
195	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016 , 128, 2798-2798	2.2	3
194	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016 , 128, 3604-3604	2.2	3
193	The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients. <i>International Journal of Hematology</i> , 2020 , 111, 293-302	2.3	3
192	Emergencies in haematology: tumour lysis syndrome. <i>British Journal of Haematology</i> , 2020 , 188, 494-500 ^{4.5}		3
191	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021 , 96, E108-E111	7.1	3
190	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1077-1081	4.4	3
189	Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. <i>American Journal of Medicine</i> , 2021 , 134, e31-e35	2.4	3

188	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 155-161	4.4	3
187	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 3068-3077	4.4	3
186	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 156	7	3
185	The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection. <i>Bone Marrow Transplantation</i> , 2017 , 52, 902-904	4.4	2
184	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017 , 92, E164-E166	7.1	2
183	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2483-2487	1.9	2
182	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1402-1405	4.7	2
181	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020 , 95, E257	7.1	2
180	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. <i>JAMA Dermatology</i> , 2020 , 156, 631-639	5.1	2
179	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. <i>British Journal of Haematology</i> , 2018 , 182, 141-145	4.5	2
178	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018 , 93, E355-E357	7.1	2
177	The Increasing Relevance of Copper Deficiency in Hematological Practice.. <i>Blood</i> , 2005 , 106, 1679-1679	2.2	2
176	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. <i>Blood</i> , 2015 , 126, 1050-1050	2.2	2
175	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 5234-5234	2.2	2
174	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. <i>Blood</i> , 2015 , 126, 736-736	2.2	2
173	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018 , 132, 2722-2722	2.2	2
172	Clinical Features and Outcomes of Isolated Myeloid Sarcoma in the United States: Analysis Using a National Dataset. <i>Blood</i> , 2016 , 128, 1618-1618	2.2	2
171	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020 , 95, E68-E72	7.1	2

170	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021 , 96, E327-E330	7.1	2
169	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 589.e1-589.e6		2
168	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1232-1239	4.7	2
167	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , 2019 , 98, 331-337	3	2
166	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 928-935	4.4	2
165	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 1-9	2.6	2
164	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018 , 93, E401-E404	7.1	2
163	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021 ,		2
162	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E433-E436	7.1	2
161	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> ,	4.5	2
160	Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2019 , 12, 155-160	2.7	1
159	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020 , 190, 244-248	4.5	1
158	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1879-1881	4.4	1
157	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1170	7.1	1
156	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , 2020 , 99, 513-518	3	1
155	Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017 , 44, 1087-1091	1.7	1
154	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017 , 92, E626-E627	7.1	1
153	Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 34-42	4.4	1

152	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. <i>Blood Cancer Journal</i> , 2022 , 12, 7	7	1
151	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 4560-4560	2.2	1
150	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 22-23	2.2	1
149	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 2927-2927	2.2	1
148	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 892-892	2.2	1
147	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009 , 114, 956-956 ^{2.2}	2.2	1
146	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010 , 116, 3557-3557	2.2	1
145	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 3095-3095	2.2	1
144	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). <i>Blood</i> , 2012 , 120, 602-602	2.2	1
143	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. <i>Blood</i> , 2013 , 122, 1732-1732	2.2	1
142	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013 , 122, 2821-2821	2.2	1
141	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013 , 122, 4049-4049	2.2	1
140	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 1923-1923	2.2	1
139	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. <i>Blood</i> , 2015 , 126, 3210-3210	2.2	1
138	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. <i>Blood</i> , 2016 , 128, 4694-4694	2.2	1
137	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016 , 128, 509-509	2.2	1
136	Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
135	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019 , 134, 4182-4182	2.2	1

134	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. <i>Blood</i> , 2010 , 116, 4109-4109	2.2	1
133	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011 , 118, 1752-1752	2.2	1
132	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 1476-1476	2.2	1
131	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013 , 122, 3873-3873	2.2	1
130	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. <i>Blood Cancer Journal</i> , 2021 , 11, 65	7	1
129	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 46	7	1
128	Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. <i>Chest</i> , 2021 , 159, 2325-2333	5.3	1
127	Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. <i>British Journal of Haematology</i> , 2021 , 195, 429-432	4.5	1
126	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 960-962	4.4	1
125	Chronic graft-versus-host disease in pancreas after kidney transplant recipients - An unrecognized entity. <i>American Journal of Transplantation</i> , 2021 , 21, 883-888	8.7	1
124	Hemolytic Uremic Syndrome Associated With O157 Infection in an Allogeneic Stem Cell Transplant Recipient. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018 , 2, 387-391	3.1	1
123	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E398-E401	7.1	1
122	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021 , 195, 413-416	4.5	1
121	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021 , 96, 1450-1460	7.1	1
120	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
119	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".. <i>Blood Cancer Journal</i> , 2022 , 12, 55	7	1
118	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1898-1907	4.4	0
117	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011 , 118, 1759-1759	2.2	0

116	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021 , 138, 3368-3368	2.2	o
115	Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. <i>Blood Cancer Journal</i> , 2021 , 11, 170	7	o
114	Systemic methotrexate absorption in a patient receiving intrathecal chemotherapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 993-995	1.9	o
113	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 63	7	o
112	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021 , 11, 122	7	o
111	Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. <i>Clinical and Experimental Dermatology</i> , 2019 , 44, e81-e88	1.8	o
110	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 274-277	4.4	o
109	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 770.e1-770.e7		o
108	Pseudo-Volkmann contracture as a complication of chronic graft-versus-host disease. <i>Dermatologic Therapy</i> , 2021 , 34, e14701	2.2	o
107	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	o
106	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , 2022 , 12, 59	7	o
105	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	o
104	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2017 , 2017, 6803804	0.7	
103	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E144-E146	7.1	
102	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. <i>International Journal of Hematology</i> , 2016 , 103, 409-15	2.3	
101	Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 835-6	1.9	
100	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. <i>Blood</i> , 2020 , 136, 26-27	2.2	
99	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 21-21	2.2	

98	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged \geq 75 Treated with Novel Agents. <i>Blood</i> , 2020 , 136, 12-13	2.2
97	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. <i>Blood</i> , 2020 , 136, 34-35	2.2
96	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. <i>Blood</i> , 2020 , 136, 43-44	2.2
95	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020 , 136, 35-36	2.2
94	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 41-42	2.2
93	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020 , 136, 30-31	2.2
92	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2020 , 136, 19-20	2.2
91	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021 , 138, 1267-1267	2.2
90	A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. <i>Blood Cancer Journal</i> , 2021 , 11, 183	7
89	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021 , 138, 3900-3900	2.2
88	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021 , 138, 1096-1096	2.2
87	Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. <i>Blood</i> , 2021 , 138, 3956-3956	2.2
86	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , 2021 , 138, 3377-3377	2.2
85	Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 5143-5143	2.2
84	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 5420-5420	2.2
83	Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. <i>Blood</i> , 2005 , 106, 1173-1173	2.2
82	Hematopathological Findings in Patients with Copper Deficiency and Hematologic Manifestations.. <i>Blood</i> , 2005 , 106, 1680-1680	2.2
81	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. <i>Blood</i> , 2005 , 106, 5422-5422	2.2

80	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. <i>Blood</i> , 2006 , 108, 116-116	2.2
79	Implications of Body Weight Calculations for Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 5445-5445	2.2
78	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. <i>Blood</i> , 2007 , 110, 2995-2995	2.2
77	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , 2018 , 132, 5510-5510	2.2
76	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. <i>Blood</i> , 2018 , 132, 2113-2113	2.2
75	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2147-2147	2.2
74	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018 , 132, 356-356	2.2
73	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , 2018 , 132, 4613-4613	2.2
72	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. <i>Blood</i> , 2018 , 132, 2678-2678	2.2
71	Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas. <i>Blood</i> , 2018 , 132, 3430-3430	2.2
70	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2689-2689	2.2
69	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4505-4505	2.2
68	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019 , 134, 3005-3005	2.2
67	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019 , 134, 367-367	2.2
66	Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes. <i>Blood</i> , 2019 , 134, 1222-1222	2.2
65	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019 , 134, 5441-5441	2.2
64	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2019 , 134, 4500-4500	2.2
63	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019 , 134, 5406-5406	2.2

62	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019 , 134, 3863-3863	2.2
61	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. <i>Blood</i> , 2019 , 134, 3300-3300	2.2
60	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019 , 134, 2588-2588	2.2
59	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019 , 134, 2013-2013	2.2
58	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015 , 126, 3730-3730	2.2
57	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015 , 126, 5260-5260	2.2
56	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015 , 126, 4062-4062	2.2
55	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4980-4980	2.2
54	Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. <i>Blood</i> , 2015 , 126, 3154-3154	2.2
53	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015 , 126, 2490-2490	2.2
52	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. <i>Blood</i> , 2015 , 126, 4910-4910	2.2
51	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. <i>Blood</i> , 2015 , 126, 1401-1401	2.2
50	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 1913-1913	2.2
49	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015 , 126, 4993-4993	2.2
48	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 5254-5254	2.2
47	A Single Institution Study of Allogeneic Hematopoietic Stem Cell Transplant for MDS and AML in Patients 60 Years of Age and Older: Impact of Disease Risk Index and Secondary Disease. <i>Blood</i> , 2015 , 126, 5532-5532	2.2
46	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. <i>Blood</i> , 2015 , 126, 4370-4370	2.2
45	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015 , 126, 3044-3044	2.2

44	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. <i>Blood</i> , 2016 , 128, 1617-1617	2.2
43	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. <i>Blood</i> , 2016 , 128, 300-300	2.2
42	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016 , 128, 996-996	2.2
41	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2016 , 128, 4653-4653	2.2
40	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016 , 128, 4593-4593	2.2
39	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016 , 128, 510-510	2.2
38	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2267-2267	2.2
37	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. <i>Blood</i> , 2016 , 128, 3599-3599	2.2
36	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. <i>Journal of Clinical Oncology</i> , 2009 , 27, 7039-7039	2.2
35	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010 , 116, 4518-4518	2.2
34	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010 , 116, 2253-2253	2.2
33	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. <i>Blood</i> , 2010 , 116, 3468-3468	2.2
32	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010 , 116, 3554-3554	2.2
31	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010 , 116, 3469-3469	2.2
30	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010 , 116, 3572-3572	2.2
29	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. <i>Blood</i> , 2011 , 118, 4120-4120	2.2
28	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. <i>Blood</i> , 2011 , 118, 4152-4152	2.2
27	Impact of Rapid Lymphocyte and Monocyte Recovery on Overall Survival Post-Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine/Melphalan Conditioning. <i>Blood</i> , 2011 , 118, 3040-3040	2.2

26	Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. <i>Blood</i> , 2012 , 120, 3555-3555	2.2
25	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 600-600	2.2
24	Loss of the Y Chromosome Predicts Lower Complete Cytogenetic Remission Rate in Patients (pts) with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2012 , 120, 4804-4804	2.2
23	Allogeneic Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. <i>Blood</i> , 2012 , 120, 2850-2850 ^{2,2}	2.2
22	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012 , 120, 4252-4252	2.2
21	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012 , 120, 599-599	2.2
20	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013 , 122, 1405-1405	2.2
19	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013 , 122, 2151-2151	2.2
18	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. <i>Blood</i> , 2013 , 122, 2145-2145	2.2
17	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. <i>Blood</i> , 2013 , 122, 2794-2794	2.2
16	Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. <i>Blood</i> , 2013 , 122, 5472-5472	2.2
15	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013 , 122, 4048-4048	2.2
14	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. <i>Blood</i> , 2013 , 122, 4955-4955	2.2
13	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. <i>Blood</i> , 2013 , 122, 2098-2098	2.2
12	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. <i>Blood</i> , 2013 , 122, 5226-5226	2.2
11	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2013 , 122, 1334-1334	2.2
10	Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2013 , 122, 916-916	2.2
9	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. <i>Blood</i> , 2013 , 122, 3375-3375	2.2

8	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. <i>Blood</i> , 2013 , 122, 2081-2081	2.2
7	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 5000-5000	2.2
6	D-index as a marker of bloodstream infections in patients with allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021 , 23, e13588	2.7
5	Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 508-510	4.4
4	Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 978-979	4.4
3	Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 1078155221995230	1.7
2	Hemoglobinuria in the Early Poststem-Cell-Transplant Period: Risk Factors and Association with Outcomes.. <i>Kidney360</i> , 2021 , 2, 1569-1575	1.8
1	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4